Boulevard Bio emerged from stealth with about $65 million in launch financing to develop multi-specific antibody therapies for B cell-driven autoimmune diseases, backed entirely by Deerfield Management affiliates. The clinical-stage company is advancing three programs built around a precision immunology platform, with its lead candidate BLVD101 a bispecific antibody targeting BAFF and APRIL. The company is initially evaluating BLVD101 in IgA nephropathy. Boulevard’s early dosing strategy emphasizes potential quarterly administration, reflecting its goal to reduce treatment burden relative to more frequent antibody regimens. Interim Phase I data were cited as supporting the possibility of once-every-twelve-weeks dosing. Deerfield structured Boulevard’s development through its internal therapeutics engine, Deerfield Discovery and Development (3DC), spanning discovery through early clinical before spinning out as an independent entity. The launch financing signals continued appetite for protein engineering and functional B cell targeting in chronic immune-mediated indications.